Introduction
Tubulysins are a family of antimitotic tetrapeptides that were isolated from Angiococcus disciformis in 2000, 1 which exhibit potent antiproliferative activity. The structures of tubulysins can be subdivided into four parts, namely Mep, Ile, Tuv, and Tup. The mode of action for tubulysins is the result of inhibition of tubulin polymerization.
1 Consequently, a large number of reports have appeared describing their total synthesis and the antitumor activities 2−5 of structural analogues 6−8 and conjugates. 9−11 These structurally challenging natural products contain multiple chiral centers, which potentially hinder their commercial development. Therefore, a number of studies have been directed towards simplifying their structures while maintaining or enhancing their antitumor potencies. Cyclizative aromatization strategies are often used in drug discovery campaigns to decrease the number of chiral centers of a drug candidate while rigidifying its structure and increasing its lipophilicity.
12,13
Most of the chiral centers present in tubulysins originate from nonnatural amino acid fragments (Tuv and Tup) that are not easy to synthesize without epimerization and side reactions occurring.
14
In our previous work, we reported that aromatization of the Tuv part of tubulysin (I, Figure) led to a dramatic loss in antitumor activity. 15 Initially, this loss of biological activity was attributed to the introduction of conformational restraint, which led to weaker interactions from the Tup fragment of tubulin. Therefore, we proposed that an intramolecular H-bond between the OH group of Tuv and the NH group of Ile might be forming a 6-membered ring intramolecular H-bond. To verify this hypothesis, a series of 2-(piperidin-4-yl)- 
Results and discussion

Chemistry
A three-step synthesis was employed to transform commercially available N -Boc-4-piperidine-carboxylic acid 1 into thiazole compound 2 (Scheme). The first step involved converting the acid functionality of 1 into an amide using an amine, dicyclohexylcarbodiimide (DCC), and ammonium chloride; the second step used Lawesson's reagent to convert the amide functionality into a thioamide group; and the third step involved refluxing with ethyl bromopyruvate in ethanol to afford a thiazole ring. The ester group of 2 was then hydrolyzed under alkaline conditions, and the resultant acid was converted into a series of amides 3a-3c using traditional peptide coupling chemistry with three amines. Methylamine (MeNH 2 ), benzylamine (PhCH 2 NH 2 ), and phenylethylamine (PhCH 2 CH 2 NH 2 ) were chosen as nucleophiles because a previous structure-activity relationship study had shown that these amines could be used to replace Tup with little effect on antitumor activity. 16, 17 N -Boc deprotection of 3a-3c with trifluoroacetic acid (TFA) was coupled with N -Boc-protected amino acids valine (Val), leucine (Leu), and phenylalanine (Phe) to afford six relatively hydrophobic peptides, 4a-4f. N -Boc deprotection of 4a-4f with TFA was followed by peptide coupling with ( D) -1-Me-piperidine-2-carboxylic acid or 4-pyridine-carboxylic acid to give amides 5a-5e, or reaction with a series of isocyanates to afford ureas 5f-5m in moderate yields.
MTT cell proliferation assay
Cell lines and cell culture
Human cancer cell lines were cultured in RPMI-1640 media supplemented with 10% fetal calf serum, penicillin (100 U/mL), and streptomycin (100 µg/mL) (GIBCO BRL, NY, USA). These cells were then incubated at 37°C in a humidified air atmosphere containing 5% CO 2 , with all cells harvested in their exponential growth phase.
Cell viability assay
Cell viability was measured using the MTT assay. Briefly, cells were seeded in multiple 96-well plates at a density of 4 × 10 4 /mL. After incubation overnight, triplicate wells were exposed to screening compounds for 72
h. MTT solution (5 mg/mL) was then added to each well and incubated for 4 h. DMSO was added to dissolve the MTT formazan product and its absorbance was measured at 570 nm using a Molecular Devices (USA) SpectraMax M5 spectrophotometer. Relative cell viability rates were calculated versus untreated controls, with 50% inhibitory concentration (IC 50 ) values calculated using Graph Pad Prism 5 (Graph Pad Software Inc., USA).
Conclusions
The structures of all compounds and their antitumor activities are listed in the Table. This series of compounds had relatively low molecular weights (between 500 and 550) and fewer stereocenters (1 or 2) when compared to tubulysins, with their antitumor activities found to be 10-fold less than that of taxol. Intermediate 4a had been shown to exhibit moderate antitumor activity in previous screening studies. Due to the N -Boc group in 4a being unstable, we tried to replace the O -in the Boc group with N -to generate a relatively stable urea group. The more stable ureas 5k and 5m showed the best potent antitumor activities, with IC 50 values of 0.2 and 0.6 µM against MCF7 cells, respectively. Comparing the three R 1 groups of these analogues, those containing phenylethylamine fragments generally possessed better activity than those with methylamine and benzylamine fragments (e.g., 5k and 5m vs. 5f and 5j). The presence of the nitro groups on the aryl rings of 5l and 5i resulted in analogues with a significant reduction in antitumor activity. We have previously shown that aromatization of the Tuv fragment led to a dramatic loss in its antitumor activity, with Ryu 18 reporting similar observations for tetrahydropyran isosteres in Tuv N -methyl tubulysin. Although the 2-(piperidin-4-yl)-thiazoles were less potent than taxol (and many other tubulysin derivatives), they were more potent than our previously prepared aromatic analogues. The observed loss of biological activity in these cyclic analogues suggested that the conformation and orientation of the central Tuv core is crucial in maintaining the antitumor activity of tubulysins.
A series of 2-(piperidin-4-yl)-thiazole-4-carboxamides have been synthesized and their antitumor activities were screened in the MTT proliferation assay, with ureas 5m and 5k showing the best antitumor activity against the MCF7 cancer cell line.
Experimental
General
The NMR spectra of the intermediates and final products of 2-(piperidin-4-yl)-thiazole-4-carboxamides in deuterated solvent were detected on a Bruker 400 or 600 MHz spectrometer (see Supporting information).
High-resolution mass spectra (HRMS) were recorded on an Agilent 6210 ESI/TOF mass spectrometer. Melting points (mp) were recorded on a Büchi B-540 melting point apparatus and are uncorrected. Flash column chromatographic separation was achieved using a silica gel from Qingdao Ocean Chemical Co. (200 to 300 mesh) with particle size from 54 to 74 µm using ethyl acetate and hexane (or petroleum ether) as the eluent.
Analytical TLC was carried out on Merck precoated silica gel 60 GF-254 using 0.25-mm-thick TLC plates. r.t. for 3 h, triethylamine (TEA) (21 mL) and ammonium chloride (NH 4 Cl) (4.16 g, 0.079 mol) were then added, and the resultant mixture was stirred for 12 h at r.t. Water (100 mL) was added and the aqueous layer was extracted with DCM (3 × 100 mL) with organic layers combined, dried over anhydrous sodium sulfate (Na 2 SO 4 ), filtered, and concentrated to afford a crude product that was purified by column chromatography (DCM:MeOH = 20:1) to afford an amide (10.11 g, 85%) as a white solid. Mp: 154-156°C.
Step 2: Lawesson's reagent (3.27 g, 8.1 mmol) was added to a solution of the above amide (3.71 g, 16 mmol) in 1,4-dioxane (50 mL) at r.t. and the reaction mixture was stirred at 50°C for 2 h. The reaction mixture was cooled to r.t., sodium bicarbonate (NaHCO 3 ) (0.80 g, 9.6 mmol) was added, and the solvent was removed under reduced pressure to afford a crude residue that was poured into a mixture of crushed ice and water. The resultant aqueous solution was extracted with DCM (3 × 50 mL) and the organic layers were combined, dried (Na 2 SO 4 ) , filtered, and concentrated to afford a crude product that was purified by column chromatography (DCM:MeOH = 10:1) to afford thioamide (3.52 g, 89%) as a white solid. Mp: 131-132°C.
Step 3 
tert-Butyl 4-(4-(phenylethylcarbamoyl)thiazol-2-yl)piperidine-1-carboxylate (3a)
Step 1. Sodium hydroxide (NaOH) (2.16 g, 0.054 mol) was added to a solution of the above ester (6.21 g, 0.018 mol) in a 1:1 mixture of THF/H 2 O (50 mL) and the reaction mixture was stirred at r.t. for 10 h. The reaction was concentrated under reduced pressure and the resultant aqueous solution was adjusted to pH 2 using 10%
HCl. Extraction with ethyl acetate (3 × 50 mL) resulted in combined organic layers that were dried (Na 2 SO 4 ) , filtered, and concentrated to afford a crude product that was used in the next step without further purification.
Step 2 The resultant reaction mixture was stirred at r.t. for 10 h before water (100 mL) was added to quench the reaction. The aqueous solution was extracted with DCM (3 × 80 mL) and the combined organic layers were then dried (Na 2 SO 4 ), filtered, and concentrated to afford a crude product that was purified by column chromatography (PE:EA 
tert-Butyl 4-(4-(benzylcarbamoyl)thiazol-2-yl)piperidine-1-carboxylate (3b)
Prepared using the same method described for 3a. 
tert-Butyl 4-(4-(methylcarbamoyl)thiazol-2-yl)piperidine-1-carboxylate (3c)
General method A for carrying out peptide coupling reactions
(S)-tert-Butyl 4-methyl-1-oxo-1-(4-(4-(phenethylcarbamoyl)thiazol-2-yl)piperidin-1-yl)pentan-2-ylcarbamate (4a)
EDC (0.68 g, 4.36 mmol), HOBt (0.39 g, 2.89 mmol), and diisopropylethylamine (DIPEA) (1 mL) were added to a solution of L -Boc-Leu (0.67 g, 2.89 mmol) in DCM (20 mL) at 0°C. The reaction mixture was stirred at r.t. for 1 h and then cooled to 0°C using an ice-water bath. Amide 3a (1.20 g, 2.89 mmol) was dissolved in 4 mL of TFA and the reaction mixture was stirred for 3 h. Excess TFA was then removed under reduced pressure to afford a residue that was diluted with DCM (25 mL) and treated with excess DIPEA in the required volume. This solution was then added to the activated acid solution at 20°C, with the resultant reaction mixture then stirred at r.t. for 18 h. Water (100 mL) was added to the reaction mixture and the aqueous solution was extracted with DCM (3 × 100 mL). The organic layers were combined, dried (Na 2 SO 4 ), filtered, and concentrated to afford a crude product that was purified by column chromatography (EA:PE = 1:3) to afford the title compound (1.35 g, 89%) as a white wax. 
(S)-tert-Butyl4-methyl-1-(4-(4-(methylcarbamoyl)thiazol-2-yl)piperidin-1-yl)-1-Oxo-pentan-
2-ylcarbamate (4d)
Prepared from Boc-L -Leu and 3c using general method A. Colorless oil (2.14 g, 87.5% 
(S)-tert-Butyl3-methyl-1-(4-(4-(methylcarbamoyl)thiazol-2-yl)piperidin-1-yl)-1-oxobutan-2-ylcarbamate (4e)
Prepared from Boc-L-Val and 3c using general method A. 
(S)-tert-Butyl1-(4-(4-(benzylcarbamoyl)thiazol-2-yl)piperidin-1-yl)-4-methyl-1-oxopentan-2-ylcarbamate (4f)
Prepared from Boc-L-Leu and 3b using general method A. Wax (2.45 g 85.5% 
(R)-1-Methyl-N-((S)-4-methyl-1-oxo-1-(4-(4-(phenethylcarbamoyl)thiazol-2-yl)piperidin-1-yl)pentan-2-yl)piperidine-2-carboxamide (5a)
Prepared from D -N-Methyl-pipecolinic acid and compound 4a using general method A. 
(R)-1-Methyl-N -((S)-3-methyl-1-oxo-1-(4-(4-(phenethylcarbamoyl)thiazole-2-yl)piperidin-1-yl)butan-2-yl)piperidine-2-carboxamide (5b)
Prepared from D -N-Methyl-pipecolinic acid and compound 4b using general method A. 
(R)-1-Methyl-N -((S)-1-oxo-1-(4-(4-(phenethylcarbamoyl) thiazol-2-yl)piperidin-1-yl)-3-phenylpropan-2-yl)piperidine-2-carboxamide (5c)
Prepared from D -N-methyl-pipecolinic acid and compound 4c using general method A. White wax (0.14 g, 87.5% 
(S)-N -(1-Oxo-1-(4-(4-(phenethylcarbamoyl)thiazol-2-yl)piperidin-1-yl)-3-phenylpropan-2-yl)isonicotinamide (5d)
Prepared from isonicotinic acid and compound 4c using general method A. White wax (0.22 g, 41% 
(S)-N -(3-Methyl-1-(4-(4-(methylcarbamoyl)thiazol-2-yl)piperidin-1-yl)-1-oxobutan-2-yl) isonicotinamide (5e)
White wax (0.15 g, 39% 1-(4-methoxyphenyl)-3-(4-methyl-1-(4-(4-(methylcarbamoyl)thiazol-2-yl) 
(S)-
(S)-1-(1-(4-(4-(Benzylcarbamoyl)thiazol-2-yl)piperidin-1-yl)-4-methyl-1-oxopentan-2-yl)-3-(4-methoxyphenyl)urea (5g)
White wax (0.18 g, 73% 
(S)-1-(4-Methoxyphenyl)-3-(4-methyl-1-oxo-1-(4-(4-(phenethylcarbamoyl)thiazol-2-yl)piperidin-1-yl)pentan-2-yl)urea (5h)
White wax (0.14 g, 65% 
(S)-1-(4-Nitrophenyl)-3-(4-methyl-1-oxo-1-(4-(4-(phenethylcarbamoyl)thiazol-2-yl)piperidin-1-yl)pentan-2-yl)urea (5i)
White wax, 78%. 1-(4-Chlorophenyl)-3-(4-methyl-1-(4-(4-(methylcarbamoyl)thiazol-2-yl)piperidin-1-yl 
(S)-
(S)-1-(4-Chlorophenyl)-3-(4-methyl-1-oxo-1-(4-(4-(phenethylcarbamoyl)thiazol-2-yl)piperidin-1-yl)pentan-2-yl)urea (5k)
White wax, yield: 75%. 
(S)-1-(3-Methyl-1-oxo-1-(4-(4-(phenethylcarbamoyl)thiazol-2-yl)piperidin-1-yl)butan-2-yl)-
3-(4-nitrophenyl)urea (5l)
White wax, 77%. 
(S)-1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(3-methyl-1-oxo-1-(4-(4-(phenethylcarbamoyl) thiazol-2-yl)piperidin-1-yl)butan-2-yl)urea (5m)
White wax, 61%. 
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